Related Experiment Videos
Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade
E M Gilbert1, J B O'Connell, M R Bristow
1Division of Cardiology, University of Utah School of Medicine, Salt Lake City 84132.
Insights
Beta-blocker therapy shows promise for idiopathic dilated cardiomyopathy, potentially improving heart function and survival. Further controlled trials are needed to confirm benefits in managing this heart condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Idiopathic dilated cardiomyopathy (IDCM) has high morbidity and mortality despite current heart failure therapies.
- Beta-blockade emerges as a potential therapeutic strategy for IDCM.
Purpose of the Study:
- To summarize the rationale for using beta-blocker therapy in IDCM.
- To review the clinical experience and evidence for beta-blocker use in IDCM.
Main Methods:
- Review of existing literature and clinical reports on beta-blocker therapy in IDCM.
- Analysis of proposed mechanisms of action for beta-blockers in IDCM.
Main Results:
- Beta-blockade may offer benefits including protection from catecholamine cardiotoxicity, improved heart rate, and reduced afterload.
- Some reports suggest long-term beta-blockade improves hemodynamics, symptoms, and survival in IDCM patients.
- Data from controlled trials remain limited, with some negative findings.
Conclusions:
- Beta-blocker therapy is a promising approach for IDCM, warranting further investigation.
- Understanding the mechanisms and clinical outcomes of beta-blockers is crucial for IDCM management.
Abstract:
Conventional therapy of patients with idiopathic dilated cardiomyopathy is currently directed at the control of heart failure. However, the morbidity and mortality of idiopathic dilated cardiomyopathy remains very high despite such interventions. One promising new approach to therapy of idiopathic dilated cardiomyopathy is beta-blockade. The potential mechanisms for benefit from beta-blockade include protection from catecholamine cardiotoxicity, upregulation of myocardial beta-adrenergic receptors, reduction in sudden death, reduction in heart rate, improved ventricular diastolic function, and reduction in afterload. Several reports have suggested that long-term beta-blockade may improve hemodynamic function, clinical symptoms, and survival in patients with idiopathic dilated cardiomyopathy. However, data from controlled trials are limited and some reports have been negative. This paper will summarize the rationale for the use of beta-blocker therapy in idiopathic dilated cardiomyopathy and review the clinical experience with this therapy.